艾昆纬iqvia

1、eyMa,Newton,EngagementManager,GSARKelseyStoddart,Consultant,GSARMarcoTravaglio,Consultant,GSARPerTroein,VP,StrategicPart。

2、plosioninresearch,4Whataredigitalhealthtechnologies,dhts,5Potentialbenefitsofdigitalhealthtechnologyinclinicaltrials6DHT。

3、holdthepotentialfortransformativebenefitsinotherdifficulttotreatdiseases,however,thecomple,journeytodeliverCART,cellther。

4、anddynamicrangeofgeopolitical,technologicalandsocialuncertainties,andinvestmentcontinuestoflowintothesector,Innovativesc。

5、ilanceTechnologySolutionsTableofcontentsIntroduction3Thecurrentregulatorylandscape4Thene,tgenerationofPV7TheIQVIAapproac。

6、OSOIANU,Consultant,StrategyConsulting,IQVIATOMROSENFELD,BusinessDevelopmentManager,StablepharmaTableofcontentsIntroducti。

7、ceuticalBusinessInsightsReportReleaseDate,Mar2025AnalyticalTimeframe,MATDec20241DisclaimerIQVIAisnotan,authorisedperson。

8、adership,IQVIAKIRSTIESCOTT,SeniorConsultant,EMEAThoughtLeadership,IQVIAMARINAKONE,Principal,StrategyConsulting,IQVIATabl。

9、IQVIAMARCOTRAVAGLIO,Consultant,GlobalSupplierAssociationRelations,IQVIAKELSEYSTODDART,Consultant,GlobalSupplierAssociati。

10、ommercemarket2Productgroups2Marketparticipants4Regulationinpharmaceuticale,commerceinEurope6Cross,borderprescriptionsint。

11、ryInnovationTechnologyANKITTYAGI,Director,RegulatoryAffairs,LabelingOperation,RegulatoryAffairsDrugDevelopmentSolutionsT。

12、withtheworldsleadingclinicalresearchandhealthcaredatacompanytodeliverasustainableandeffectiveweightmanagementservice,2Ap。

13、MARCROHDE,Director,StrategicSiteSolutionsTableofcontentsPreface,AdvancingGermanyasatriallocationtogether,3E,ecutivesumma。

14、STASIACHERNYATINA,SeniorConsultant,IQVIAMedTechTableofcontentsE,ecutivesummary1PotentialimpactofnewtariffsonMedTech1Cana。

15、trategy,IQVIAPart1ofa4,partserieshighlightingkeyinnovationsinclinicaltrialsTableofcontentsOverview1Howthebarwasraised,en。

16、Characteristicsofcurrentcliniclandscape3Conclusion7References8Authors9AboutIQVIA9,1SincetheendoftheCOVIDlockdown,thephar。

17、IQVIAChinaTableofcontentsIntroductiontoChinasMedTechmarket1MountingfinancialpressuresonChinaspublicmedicalinsurance1Volu。

18、ction1SectionI,Currentchallengesandtrendsinglobalhealth2Salientglobalhealthchallenges2Addressingglobalhealthchallengesac。

19、TableofcontentsIntroduction1Prerequisitesforsuccessinthemarketof2030,Microsegmentsandpersonalization2Theothertransformat。

20、Introduction1Findings2Channeltrends3Impactofstatecontractpharmacybills5Diseaseareas6Limitations7Discussionandfutureoutlo。

21、tmentforchronicdiseasesandnewnoveltreatmentsbecomeavailable,However,patientsstillfacesignificantbarrierstoaccessingmedic。

22、床急需,助力产学研融合创新上已经取得初步进展,2四,行业领头制药,医疗器械企业积极参与港澳药械通,落地过程中面临一些困难,2五,完善健全港澳药械通各个环节的政策与制度,3第一章粤港澳大湾区的国家战略定位与发展情况第一章粤港澳大湾区的国家战略。

23、OncologyCenterofE,cellenceDAVIDALSADIUS,MD,PhD,SeniorMedicalDirector,SolidTumorLead,Hematology,OncologyCenterofE,cellenc。

24、ionondisclosurestatement2025,Allrightsreserved,IQVIAisaregisteredtrademarkofIQVIAInc,intheUnitedStates,theEuropeanUnion。

25、edinvestmentinscreeningandearlydiagnosis,accesstocare,andnoveltreatmentmodalitieswithimprovedclinicalbenefits,Asaresult。

26、Rarediseaseoverview3Whatistheburdenofrarediseases,3Howarerarediseasesdefined,3RareDiseaseManagementinAPAC4Howmatureisthe。

27、withtheiruse,Thesebiosimilarshavealsoprovidedsubstantialsavingsfortheoverallhealthcaresystem,In2023,IQVIAInstitutepublis。

28、uamharisquuntur3Cumquenethictesedipsum3Temautfaccusiumque3Piciisreprehenetvoloimquaeradolorporemquam4Niaspercienisadi4Se。

29、CommercialStrategyTransformation,IQVIABRIANNEEDHAM,AssociatePrincipal,StrategyConsulting,IQVIATableofcontentsE,ecutivesu。

30、新药特点的期待,242,早期乳腺癌患者对新药的接受度,25第三章患者的信息需求及信息渠道偏好第三章患者的信息需求及信息渠道偏好,271,早期乳腺癌患者的信息需求,272,早期乳腺癌患者的信息渠道偏好,28第四章第四章结语结语,直面挑战,点亮。

31、iticaldeterminantofhealthoutcomes,particularlyinlow,andmiddle,incomecountries,LMICs,whicharehometoover80,oftheglobalpopu。

32、inessInsightsReportReleaseDate,Jun2025AnalyticalTimeframe,MATMar20251DisclaimerIQVIAisnotan,authorisedperson,forthepurpo。

33、ntralissuesinhealthpolicyandinternationaltradediscussionsinrecentyears,includingthepotentialreshapingofglobalmarketsandd。

34、concepttocare,Howdigitaltwinsworkinhealthcare2Real,worldapplications,marketdrivers,andindustrymomentum3Challengesandcons。

35、rveyMa,Newton,Principal,StrategicPartners,GSAR,KelseyStoddart,SrConsultant,GlobalSupplierAssociationRelationsMarcoTravag。

36、tentsIntroduction1Prevailingwinds2Thesilversurge2Middleclasse,pansion2Geopoliticalheadwinds3Technologysforwardmarch35key。

37、artofthispublicationmaybereproducedortransmittedinanyformorbyanymeans,electronicormechanical,includingphotocopy,recordin。

38、egy,AsiaENALYNANG,MD,FPCP,FPSG,MedicalDirector,MedicalScienceandStrategy,AsiaCHARUGAUTAM,MBBS,MD,DNB,SeniorMedicalDirect。

39、IATableofcontentsSummary3Definingtheobesityepidemic4Factorscontributingtotheobesityepidemic5Treatmentlandscapeforobesity。

40、HEEYOONG,AssociatePrincipal,RealWorldInsights,IQVIAAsiaPacificDR,ALANFONG,ConsultantCardiologist,SarawakHeartCentrePROF。

41、816,881,717,650,4EBITDA,MM,3,684,03,796,53,965,54,164,0EPS11,1311,8912,9814,17PE16,8,15,7,14,4,13,2,4KeyInsights,IQV2Q25。

42、in2024revealedgeographicaldifferencesintheavailabilityofoncologynovelactivesubstances,NAS,acrossselectEUcountries,Austra。

43、IQVIADR,PRAVINDRAAWASTHI,Principal,MarketCompetitiveIntelligence,IQVIATableofcontentsE,ecutivesummary1Surveymethodology2。

44、URJA,Consultant,StrategyConsulting,IQVIAADIVITIYABIHAGARA,MedicalWriter2,RWEMedicalandScientificWriting,IQVIATableofcont。

45、年将成全球疾病首位,中国流行病学调查显示,成人抑郁症的终生患病率为3,4,约有九千万患者,占全球近13,是全球患者人群最大的国家2,1,1,2,抑郁症,抑郁症,MDD,治疗存在,治疗存在巨大未满足需求巨大未满足需求,中枢神经系统,CNS,是。

46、书篇章摘要肾病患者诊疗现状蓝皮书篇章摘要11二,二,中国中国IgAIgA肾病患者诊疗现状研究发现肾病患者诊疗现状研究发现331,研究方法与数据来源32,IgA肾病患者诊断现状研究发现32,1从首次意识肾脏异常到首次就医42,2从首次就医到首。

47、usinessDevelopment,IQVIAMedTechTableofcontentsE,ecutivesummary1ProjectedcorporateimpactsreflectedinMedTechquarterlyearni。

48、tiesforlanguagesolutions2Bestpracticesinsourcinglanguagesolutions3Strategicsourcingandplanning3Vendorselectionprocess5Cr。

49、tmentevolvingrapidlythroughmedicaladvances,thevalueofpatient,centeredcareisbeingincreasinglyrecognizednotonlyinacademicl。

50、yst,GlobalMarketInsights,IQVIASHIKHAKASHYAP,Manager,GlobalMarketInsights,IQVIA2,IQVIAPharmaDealsTableofcontentsIntroduct。

51、LUTZMAYER,SeniorConsultant,EMEAThoughtLeadership,IQVIATableofcontentsIntroduction1Unmetneedisaccelerating1Pushingthefron。

52、oughtLeadershipOLIVIAMEADOWCROFT,Consultant,ObesityProgramManagerMOHITAGARWAL,Consultant,EMEAThoughtLeadershipCAROLINENO。